TELAPREVIR相关论文
...
Mutational diversity of NSSA and NS3 during triple therapy (telaprevir, pegylated-interferon-alpha 2
Background and aim: Telaprevir, a nonstructural (NS)3/4A protease inhibitor, is a direct-acting antiviral drug that inhi......
已经完成的Ⅱ期临床实验结果表明,Vertex制药公司率先研发的telaprevir(曾用代号VX-950;LY-570310;MP-424)对慢性丙型肝炎患者有良......
期刊
在Vertex/Tibtec公司的蛋白酶抑制剂telaprevir的第3个(也是最后1个)Ⅲ期临床试验中,该药已达到有效治疗丙型肝炎(HCV)1型患者的预......
阜阳市局 £4a 局长——_MINtkMMtgj’#lnH$B——q.M——D收束志不他只邀狲位J则【科校为先导推动地租工作.B为广为戳民U用凶盼引眯B.......
直接作用抗病毒药(DAA)可抑制丙型肝炎病毒(HCV)基因1型复制,从而改善了初治和有过治疗史的丙肝患者持续病毒学应答(SVR)率。事实......
Telaprevir是美国Vertex制药公司开发的一种丙型肝炎病毒(HCV)NS3/4A丝氨酸蛋白酶抑制剂,能抑制HCV的病毒复制。在欧洲和美国开展......
目的 了解Telaprevir联合聚乙二醇干扰素(Peg-IFN)α、利巴韦林对基因Ⅰ型HCV感染慢性丙型肝炎患者的疗效及安全性. 方法 采用Meta......
(2S)-2-环己基-N-(2-吡嗪基羰基)甘氨酰-3-甲基-L-缬氨酸(2)与(1S,3aR,6a S)-八氢环戊烯并[c]吡咯-1-羧酸乙酯盐酸盐(3)缩合得到(1S,3aR,6a S)-......
丙肝病毒(HCV ) 感染世界范围的约 2 亿个人。基于干扰素的治疗在过去的二十年统治了。然而,全面反应率仍然保持非最优。由于从学术......
有 ribavirin 和干扰素(三倍的治疗) 的 boceprevir 或 telaprevir 的联合被显示了为遗传型 1 丙肝的处理比 ribavirin+interferon......
Aplastic anemia and severe pancytopenia during treatmentwith peg-interferon, ribavirin and telaprevi
Telaprevir and Boceprevir are the first direct actingantivirals approved for chronic hepatitis C in combinationwith peg-......
AIM To characterize management of telaprevir (TVR)-based triple therapy of hepatitis C virus (HCV) reinfectionafter liver tr......
Factors associated with success of telaprevir-and boceprevir-based triple therapy for hepatitis C vi
AIM To evaluate new therapies for hepatitis C virus(HCV), data about real-world outcomes are needed.METHODS Outcomes of ......
Hepatitis C treatment in the elderly: New possibilities andcontroversies towards interferon-free reg
Due to the progressive aging of the hepatitis C virus(HCV) population which have acquired the infectionduring its maximum ......
Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chr
AIM To evaluate and compare the efficacy and safety of telaprevir(TVR)-and simeprevir(SMV)-based triple therapies in eld......
在Vertex/Tibtec公司的蛋白酶抑制剂telaprevir的第3个(也是最后1个)Ⅲ期临床试验中,该药已达到有效治疗丙型肝炎(HCV)1型患者的预期指标......
期刊
已经完成的Ⅱ期临床实验结果表明,Vertex制药公司率先研发的telaprevir(曾用代号VX-950;LY-570310;MP-424)对慢性丙型肝炎患者有良好的......
期刊
Effectiveness and safety of first-generation proteaseinhibitors in clinical practice: Hepatitis C vi
AIM To evaluates the effectiveness and safety of thefirst generation, NS3/4A protease inhibitors (PIs) inclinical practice......
We report a case of successful treatment of chronic hepatitis C infection with telaprevir-based triple therapy in a pati......
Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immuno
AIM: To evaluate virological response to telaprevir or boceprevir in combination with pegylated interferon and ribavirin......
<正>【据Hepotology 2012年12月报道】题:经治失败的丙肝患者应用Telaprevir再治疗的效果和耐药特点:来自REALIZE临床试验结果(作......
<正>【据Hepatology2012年9月报道】题:基因1型慢性丙型肝炎初治患者用Boceprevir或Telaprevir治疗的成本效果分析(作者CammàC等)......
全球丙型肝炎病毒(Hepatitis C Virus,HCV)感染者超过1.8亿,HCV感染可导致慢性肝病、肝硬化和肝细胞癌(HCC)等疾病,已成为严重的健康问题。......